(12) United States Patent (10) Patent No.: US 8,022,053 B2 Mueller Et Al
Total Page:16
File Type:pdf, Size:1020Kb
US008022053B2 (12) United States Patent (10) Patent No.: US 8,022,053 B2 Mueller et al. (45) Date of Patent: Sep. 20, 2011 (54) ORAL SOLID DOSAGE FORMS CONTAINING 4,755,386 A 7, 1988 Hsiao et al. A LOW DOSE OF ESTRADIOL 5,073,374. A 12/1991 McCarty 5,776.492. A 7/1998 Betzing et al. 5,891,867 A * 4/1999 Lanquetin et al. ............ 514,170 (75) Inventors: Kristina Mueller, Berlin (DE); Torsten 5,891,868 A 4/1999 Cummings et al. Wagner, Berlin (DE); Adrian Funke, 6,030,988 A 2/2000 Gilis et al. Berlin (DE); Christian Zurth, Berlin 6,060,077 A * 5/2000 Meignant ...................... 424/434 (DE) 6,323,366 B1 1 1/2001 Wolfe et al. 6,326,366 B1* 12/2001 Potter et al. ................... 514, 182 6,455,069 B1 9, 2002 Michaud et al. (73) Assignee: Bayer Schering Pharma 6,521,253 B1 2/2003 Forsman et al. Aktiengesellschaft, Berlin (DE) 6,558,707 B1 5/2003 Thosar et al. 6,653,298 B2 * 1 1/2003 Potter et al. ................... 514, 182 (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 (Continued) U.S.C. 154(b) by 1017 days. FOREIGN PATENT DOCUMENTS (21) Appl. No.: 11/262,952 EP 04.078O140 11, 2004 (Continued) (22) Filed: Nov. 1, 2005 OTHER PUBLICATIONS (65) Prior Publication Data The Contraception Report, “Bioecuivalence between Brand-Name US 2006/O 111334 A1 May 25, 2006 and Generic OCs.” Jun. 2002, 13(2), 6-8.* Related U.S. Application Data (Continued) (60) Provisional application No. 60/623,858, filed on Nov. Primary Examiner — San-Ming Hui 2, 2004. Assistant Examiner — Paul Zarek (30) Foreign Application Priority Data (74) Attorney, Agent, or Firm — Millen, White, Zelano & Branigan, P.C. Nov. 2, 2004 (EP) ..................................... O4O78O14 (57) ABSTRACT (51) Int. Cl. A6 IK3I/56 (2006.01) The present invention relates to oral Solid dosage forms con (52) U.S. Cl. ....................................................... S14f182 taining a very low dose of estradiol. The dosage forms are (58) Field of Classification Search ................... 514f182 formulated in a manner so as to avoid degradation of the See application file for complete search history. estradiol and to minimise the content of polyvinylpyrroli done, while still achieving similar fast dissolution of the (56) References Cited estradiol. The dosage forms are useful in preventing or treat ing a physical condition in a woman caused by insufficient U.S. PATENT DOCUMENTS endogenous levels of estradiol. 2,096,744 A 10, 1937 Hildebrandt et al. 3,318,925 A 5, 1967 Anner et al. 25 Claims, 1 Drawing Sheet Conc. pg/mL) 10 O 1 2 3 4 5 6 8 10 12 14 24 36 48 Time (hour US 8,022,053 B2 Page 2 U.S. PATENT DOCUMENTS Chaumeil JC, “Micronization: A Method of Improving the Bioavail 6,716,453 B1 4/2004 Harden et al. ability of Poorly Soluble Drugs.” Methods and Findings in Experi 6,962.908 B2 11/2005 Aloba et al. mental and Clinical Pharmacology, 1998, 20(3), 211-215.* 6,987,101 B1 1/2006 Nashed Vagifem (R) product information sheet, Jul. 2003.* 2002/0173487 A1* 11/2002 Backenfeld et al. ............ 514/58 Moneghini, et al.: “Studies in Dissolution Enhancement of Atenolol. 2003. O104058 A1* 6, 2003 Rudnic et al. 424/468 Part I.” International Journal of Pharmceutics 175; 1998; pp. 177 2003. O144258 A1* 7, 2003 Hei1 et al. ... 514f1 70 183. 2003,019 1103 A1* 10, 2003 Grubb et al. 514, 182 Voigt, et al., “Granulometrische Erfassung Des Einflusses Von 2005/0020554 A1 1/2005 Ahmed et al. ................ 514, 182 Polyvinylpyrrollidon Auf Die LoeSungsgeschwindigkeit FOREIGN PATENT DOCUMENTS Schwerloeslicher Arzneistoffe.” Wissenschaftsbereich Pharmazie FR 2823976 A 10, 2002 35; 1980; pp. 311-312. RU 2101013 C1 11F1996 “Novel Hormone Composition and Use Thereof. Summary of FR WO WO97, 12600 A1 4f1997 2823796. WO WO98,04268 * 2/1998 Loyola University Health System Article: Drospirenone/Ethinyl WO WO 98.27929 7, 1998 WO WO99,26631 A1 6, 1999 Estradiol (Oral) (Tablet); 2005. WO WOO1, 52857 A1 T 2001 NCBI Article: The Effect of a Novel Vaginal Ring Delivering WO WO O2/47632 A1 6, 2002 Oestradiol Acetate on Climacteric Symptoms in Postmenopausal WO WO O2/49675 A1 6, 2002 Women. Buckler H. Al-AZZawi F; UKVR Multicentre Trial Group. WO WOO3,055495 T 2003 Department of Endocrinology, University of Manchester and Hope OTHER PUBLICATIONS Hospital, Stott Lane, Salford M68HD, UK, 2003. BJOG Article: An International Journal of Obstetrics & Gynaecology Karalis V. Macheras P. Van Peer A, and Shah VP, “Bioavailability and vol. 110 p. 753–Aug. 2003 doi10.1111?. 1471-0528.2003.02408.x bioecuivalence: focus on physiological factors and variability.” Phar vol. 110 Issue 8. maceutical Research, Aug. 2008 (Epub Jun. 2008), 25(8), 1956 Estradiol Article: What is the most important information I should 1962.* know about estradiol?, 2006. Timmer CJ and Geurts TB, “Bioeduivalence assessment of three Article: MedicineNet.com article: Estradiol/ethinyl Estradiol-Oral, different estradiol formulations in postmenopausal women in an 2005. open, randomized, single-dose, 3-way cross-over study.” European Article: Drug Digest, 2005. Journal of Drug Metabolism and Pharmacokinetics, Jan. 3, 1999, 24(1), 47-53.* * cited by examiner U.S. Patent Sep. 20, 2011 US 8,022,053 B2 ConC. pg/mL) 10 O 0 1 2 3 4 5 6 8 10 12 14 24, 36 48 Time (hour Fig. 1 US 8,022,053 B2 1. 2 ORAL SOLID DOSAGE FORMS CONTAINING Successfully determined by performing linear extrapolation A LOW DOSE OF ESTRADIOL of known serum levels resulting from daily oral administra tion of 1-3 mg estradiol. This application claims the benefit of the filing date of U.S. When formulating a solid oral dosage form intended for Provisional Application Ser. No. 60/623,858 filed Nov. 2, 5 immediate release of a low dose of a highly hydrophobic 2004. active ingredient, such as estradiol, the person skilled in phar maceutical Science would consideri) increasing the disinte FIELD OF INVENTION gration of the oral dosage form into Smaller fragments, ii) increasing the release of the active ingredient into the gastric The present invention relates to pharmaceutical composi fluid, and iii) increasing the dissolution rate of the active tions, in particular oral Solid dosage forms, comprising a low ingredient in the gastric fluid so as to prevent that the active dose estradiol. The dosage forms of the present invention ingredient enters the lower intestinal tract before being allow for good chemical stability of the estradiol during stor absorbed in the upper intestinal tract, which is the primary site age while still achieving a high dissolution rate of the estra of absorption for large molecules. diol- in0 water. 15 In order to do so, the person skilled in pharmaceutical Science would, as his primary option, choose to formulate the BACKGROUND OF THE INVENTION Solid dosage form using micronised material of the active ingredient to provide a high Surface area. The high Surface Pharmaceutical dosage forms containing naturally or syn area will then allow for a rapid dissolution. thetically derived steroidal hormones often contain a low As a second option, the scientist would formulate the solid dose of these active ingredients. In the present invention the dosage form using excipients promoting disintegration in dose of estradiol is significantly lower than what has so far combination with excipients promoting the wetting/solubilis been administered orally in the treatment of physical condi ing of the active ingredient in water or in gastric fluid. Nor tions associated with insufficient endogenous levels of estro- 25 mally, the scientist would select polyvinylpyrrolidone (PVP), gens in Women. which is an excipient exhibiting solubilising effect (improv According to U.S. Pat. No. 5,891,868 (Cummings et al.), ing the wettability), but also binding capacity making this the risk of bone fractures in postmenopausal women was excipient a “first choice” option, in particularly, when formu reduced by administering transdermally about 20 ug of estra lating oral Solid dosage forms of highly hydrophobic drugs. diol, or even less than about 20 g of estradiol, per day. 30 The solubilising effect of polyvinylpyrrolidone is well Transdermal administration resulted in effective serum levels described in the literature. For example, polyvinylpyrroli in the range between 5 and 20 pg/ml, which remained within done has been shown to improve the solubility and dissolu that range for an extended period of time. Cummings et al. tion rate of atenolol (Moneghini et al. IntJ Pharm 175; 1998: also suggested to administer the exogenous estrogen by other 177-183) and to increase the dissolution of prednisolone, Suitable routes, for example by oral or parenteral administra 35 nitrofurantoine and nitrofural considerably from gels con tion, but Cummings et al. further stated that “the estrogen taining 1-10% w/w of polyvinylpyrrolidone (Voigt etal. Phar should be administered parenterally or transdermally rather mazie 35; 1980:311-312). than orally. The former routes of administration are preferred WO 01/52857 describes manufacturing of oral dosage over oral administration because oral administration of estro forms containing 1 to 3 mg of estradiol with polyvinylpyr 40 rollidone 25000. gen may lead to increased levels of sex hormone binding However, the present inventors have found that when a globulin. Sex hormone binding globulin may diminish the lower dose of estradiol is applied in a tablet formulation beneficial effects of administering estrogen to postmeno similar to those described in example 1 of WO 01/52857, a pausal Subjects, particularly Subjects exhibiting signs of significant loss of estradiol during storage is detected, i.e. the osteoporosis or loss of bone mineral density'.